Öz
Amaç:
Bu çalışmadaki amacımız, kolorektal kanserde Kirsten sıçan sarkom viral onkogeni (KRAS) ekson-2 mutasyonunun 18F-florodeoksiglukoz (FDG) tutulum paternlerini, toplam lezyon glikolizini ve metabolik tümör hacmini etkileyip etkilemediğini değerlendirmektir
Yöntem:
Bu retrospektif çalışmaya 52 kolorektal kanserli hasta dahil edildi. Maksimum standartlaştırılmış uptake değerleri (SUDmaks), tümör-karaciğer parankim SUVmaks oranları (TKO), retansiyon indeksi (RI), metabolik tümör hacimleri (MTV), toplam lezyon glikoliz (TLG) ve glukozla düzeltilmiş TLG’ler gibi çift zamanlı 18F-FDG pozitron emisyon tomografi/bilgisayarlı tomografi (PET/BT) parametreleri ölçüldü.
Bulgular:
Mutasyona uğramış ve vahşi tip kolon kanseri arasında PET/BT görüntüleme parametrelerinde istatistiksel fark yoktu, ancak RI ve RI (TKO) değerleri vahşi tipte mutasyona uğramış tipten istatiksel olarak daha yüksekti. KRAS ekson-2 vahşi tip rektum kanseri hastalarında düşük MTV vardı (p=0,044). KRAS mutasyon durumu MTV ile korele idi (r=-0,277, p=0,048). ROC eğrileri analizi, MTV ve MTV’nin (%) KRAS ekson-2 mutasyon durumunu doğru bir şekilde öngördüğünü gösterdi.
Sonuç:
Çalışmamızda hem kolon hem de rektum kanserli hastalarda KRAS ekson-2 mutasyon durumu ile artmış 18F-FDG tutulumu arasında bir ilişki bulamasak da, KRAS ekson-2 vahşi tip kolon kanserli hastalarda ilginç bir şekilde zamanla artan 18F-FDG tutulumu görülmüştür. KRAS ekson-2 mutasyon durumu ile MTV arasında bir korelasyon bulsak bile, bu çok güçlü değildi.
Anahtar Kelimeler: Florodeoksiglukoz F18, insan, KRAS proteini, kolorektal neoplazmalar, pozitron emisyon tomografi
Kaynakça
Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005;16(3):481-488.
Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti--epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol 2016;34(2):179-185.
Chen SW, Chiang HC, Chen WTL, Hsieh TC, Yen KY, Chiang SF, et al. Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med 2014;39(8):685-689.
Chen SW, Lin CY, Ho CM, Chang YS, Yang SF, Kao CH, et al. Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT. Clin Nucl Med 2015;40(8):621-626.
Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, et al. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res 2012;18(6):1696-1703.
Kawada K, Toda K, Nakamoto Y, Iwamoto M, Hatano E, Chen F, et al. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer. J Nucl Med 2015;56(9):1322-1327.
Krikelis D, Skoura E, Kotoula V, Rondogianni P, Pianou N, Samartzis A, et al. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients. Anticancer Res 2014;34(5):2571-2579.
Lee JH, Kang J, Baik SH, Lee KY, Lim BJ, Jeon TJ, et al. Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level. Medicine (Baltimore) 2016;95(1):e2236.
Miles KA, Ganeshan B, Rodriguez-Justo M, Goh VJ, Ziauddin Z, Engledow A, et al. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. J Nucl Med 2014;55(3):386-391.
Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imagin 1999;2(3):159-171.
Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med 2011;36(5):331-336.
Kiaris H, Spandidos DA. Mutations of ras genes in human tumors (review). Int J Oncol 1995;7(3):413-421.
Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327(6120):298-303.
Peng N, Zhao X. Comparison of K-ras mutations in lung, colorectal and gastric cancer. Oncol Lett 2014;8(2):561-565.
Vincenzi B, Cremolini C, Sartore-Bianchi A, Russo A, Mannavola F, Perrone G, et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 2015;6(31):31604-31612.
Yoshino T, Muro K, Yamaguchi K, Nishina T, Denda T, Kudo T, et al. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study. EBioMedicine 2015;2(4):317-323.
Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009;50(11):1820-1827.
Tatlidil R, Jadvar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 2002;224(3):783-787.
Iwamoto M, Kawada K, Nakamoto Y, Itatani Y, Inamoto S, Toda K, et al. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med 2014;55(12):2038-2044.
Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325(5947):1555-1559.
Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis.Abdom Radiol (NY) 2019;44(5):1703-1711.
Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review. Oncologist 2011;16(9):1239-1249.
Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011;34(1-2):61-66.
Bossard C, Küry S, Jamet P, Senellart H, Airaud F, Ramée JF, et al. Delineation of the infrequent mosaicism of KRAS mutational status in metastatic colorectal adenocarcinomas. J Clin Pathol 2012;65(5):466-469.
Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011;54(9):1170-1178.
Sundström M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, et al. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 2010;10:660.
